echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > J Clin Oncol: ROCK2 inhibitor berudil can effectively treat refractory chronic graft-versus-host disease

    J Clin Oncol: ROCK2 inhibitor berudil can effectively treat refractory chronic graft-versus-host disease

    • Last Update: 2021-05-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The rho-related coiled-coil protein kinase 2 (ROCK2) signaling pathway regulates the Th17/regulatory T cell balance and controls the fibrotic pathway.
    The selective inhibition of ROCK2 with belumosudil (KD025) may provide a new method for the treatment of chronic graft-versus-host disease (cGVHD).

    A Phase IIa, open-label dose exploratory study " ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease " published in the " Journal of Clinical Oncology " recently , aimed at clarifying Beludi The dose and effect of ER for cGVHD patients who have previously received first-line third-line therapy (LOT).
    The primary endpoint is the overall response rate (ORR).

    Journal of Clinical Oncology Journal of Clinical Oncology ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease

    A total of 54 cGVHD patients were recruited, and the median time from diagnosis of cGVHD to enrollment was 20 months.
    78% of patients had severe cGVHD, 50% of patients involved at least 4 organs, 73% of patients had last LOT refractory cGVHD, and 50% of patients had received at least third-line treatment in the past.

    Remission rate of different groups

    Remission rate of different groups

    With a median follow-up of 29 months, the ORR (95% CI) of berudil at doses of 200 mg·1/day, 200 mg·2/day, and 400 mg·1/day were 65% (38%- 86%), 69% (41%-89%) and 62% (38%-82%) .

    The ORR (95% CI) of berudil at doses of 200 mg·1/day, 200 mg·2/day, and 400 mg·1/day were 65% (38%-86%) and 69% ( 41%-89%) and 62% (38%-82%)

    Duration of remission of berudil treatment

    Duration of remission of berudil treatment

    The remission rate is clinically significant, with a median duration of remission of 35 weeks, and is associated with improved quality of life and reduced corticosteroid (CS) consumption.
    CS treatment was discontinued in 19% of patients.

    The failure-free survival rates at 6 months and 12 months were 76% (62%-85%) and 47% (33%-60%), respectively.
    The 2-year overall survival rate was 82% (69%-90%).

    Remission rate of different organs

    Remission rate of different organs

    Beludil is well tolerated and the incidence of cytopenias is low.
    Unexpected adverse reactions did not occur, and the risk of
    infection (including cytomegalovirus infection and reactivation) did not increase significantly.

    infection

    In short, berudil treatment can enable patients to obtain high ORR and overall survival rate, and at the same time can improve the quality of life of patients, reduce CS dose and limit toxicity .
    The results of this study suggest that berudil may be an effective choice for patients with refractory cGVHD.

    Beludil treatment can provide patients with high ORR and overall survival rate, and at the same time can improve the quality of life of patients, reduce CS dose and limit toxicity

    Original source:

    Original source:

    Madan Jagasia, et al.
    org/licenses/by-nc-nd/4.
    0/" target="_blank" rel="noopener">ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease .
    J Clin Oncol.
    https://creativecommons.
    org/licenses/by-nc-nd/4.
    0/

    org/licenses/by-nc-nd/4.
    0/" target="_blank" rel="noopener">ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease

    in this message
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.